ENDEAVOR III Trial reports key findings on new-generation stent
...h zotarolimus, a medication that, like the Cyphers sirolimus coating, reduces renarrowing of the artery by preventing the growth of scar tissue inside the stent. Initial data showed that procedural success was higher with the new Endeavor stent, which is more flexible and is considered easier to implant tha...Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression
...ing stable patients from calcineurin inhibitors to sirolimus showed consistent improvement of kidney function. ...ion. A second study found gradual transition to sirolimus in 29 patients also greatly impaired the development of the proliferative changes found in transplan...Studies highlight 'real world' use, safety of drug-eluting stents
...son & Johnson), which slowly releases a coating of sirolimus into the artery wall to prevent overgrowth of scar tissue and renarrowing of the artery. Some 34 percent of patients in the registry have diabetes, 33 percent have a history of heart attack, and well over half have previously had a catheter-based int...Diabetes researchers pioneer islet cell xenotransplantation in primate studies
...ntibody, while maintaining immunosuppression using sirolimus and belatacept (a second-generation high affinity derivative of CTLA4-Ig)9-11 on diabetic rhesus macaques transplanted with neonatal porcine islets....Comparison of drug-releasing coronary stents show similar effectiveness
Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients...the February 22 issue of JAMA. Stents that release sirolimus or paclitaxel have been known to be more effective than bare metal stents in improving angiographic ...Leading immunosuppressant CellCept significantly extends the lifespan of transplanted kidneys
...vival was 85.9% versus 80.3% with patients taking sirolimus + tacrolimus immunosuppressants. The outcome was even better for higher risk patients with a kidney survival rate of 74.5% vs 57.5%[i]. The new data were presented at the European Society for Organ Transplantation (ESOT), Geneva, Switzerland. Previou...Steroid-free regimen with CellCept found comparable to standard therapy in liver transplantation
...cy and safety of a regimen of CellCept with either sirolimus or standard calcineurin inhibitors (CNI). Investigators will evaluate the effect of these regimens on preservation of renal function and prevention of acute rejection, organ loss and patient survival. CellCept A Cornerstone of Treatment for 10 Y...Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants
...croemulsion (CYA) + MMF and steroids, and 3) TAC + sirolimus (SRL) and steroids. The primary purpose of this study was to compare the incidence of rejection requiring treatment, as measured by the International Society for Heart and Lung Transplantation (ISHLT) grading system. Humoral rejection has been r...Drug-releasing stents showing higher complication rate than clinical trials indicated
...ercent) had stent thrombosis (9 [0.8 percent] with sirolimus and 20 [1.7 percent] with paclitaxel, substantiall...n major clinical trials (0.4 percent at 1 year for sirolimus and 0.6 percent at 9 months for paclitaxel). Among these 29 patients, 13 died (case fatality rate, ...